What Happens to Weight When You Stop GLP-1 Drugs? A Review of the Evidence
Randomized trial evidence shows significant weight regain after stopping liraglutide, semaglutide, or tirzepatide, raising concerns about long-term treatment plans.
Quick Facts
What This Study Found
Weight regain after GLP-1 drug discontinuation is substantial and consistent across randomized trials for liraglutide, semaglutide, and tirzepatide.
Key Numbers
Reviews RCTs for liraglutide, semaglutide, and tirzepatide; weight regain of approximately two-thirds of lost weight within 1-2 years post-discontinuation.
How They Did This
Narrative review of RCTs from PubMed, Cochrane Library, and Google Scholar published in the last 10 years.
Why This Research Matters
If weight returns after stopping, patients face a choice between lifelong medication use or accepting weight regain — with major cost and safety implications.
The Bigger Picture
The weight regain problem challenges the healthcare system to decide whether GLP-1 drugs are lifelong commitments or bridges to other interventions.
What This Study Doesn't Tell Us
Narrative review — does not quantitatively pool results. Limited long-term post-discontinuation data available.
Questions This Raises
- ?Can lifestyle changes during treatment prevent weight regain after stopping?
- ?Is intermittent dosing a viable strategy to reduce costs while maintaining benefits?
Trust & Context
- Key Stat:
- Weight regain Consistent across RCTs for all three agents after treatment discontinuation
- Evidence Grade:
- Narrative review of RCTs — high-quality source studies but review methodology is not systematic.
- Study Age:
- Published in 2025, addressing one of the most pressing questions about GLP-1 obesity treatment.
- Original Title:
- Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.
- Published In:
- Journal of clinical medicine, 14(11) (2025)
- Authors:
- Quarenghi, Massimo, Capelli, Silvia, Galligani, Giulia, Giana, Arianna, Preatoni, Giorgia, Turri Quarenghi, Rosamaria
- Database ID:
- RPEP-13151
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Will I gain weight back if I stop Ozempic or Wegovy?
Research consistently shows significant weight regain after stopping GLP-1 drugs, though the amount and speed vary by medication.
Do I have to take GLP-1 drugs forever?
Current evidence suggests long-term use is needed to maintain weight loss. Discuss with your doctor whether lifelong treatment or alternative strategies are right for you.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13151APA
Quarenghi, Massimo; Capelli, Silvia; Galligani, Giulia; Giana, Arianna; Preatoni, Giorgia; Turri Quarenghi, Rosamaria. (2025). Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.. Journal of clinical medicine, 14(11). https://doi.org/10.3390/jcm14113791
MLA
Quarenghi, Massimo, et al. "Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.." Journal of clinical medicine, 2025. https://doi.org/10.3390/jcm14113791
RethinkPeptides
RethinkPeptides Research Database. "Weight Regain After Liraglutide, Semaglutide or Tirzepatide ..." RPEP-13151. Retrieved from https://rethinkpeptides.com/research/quarenghi-2025-weight-regain-after-liraglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.